A Trial to Evaluate the Safety and Efficacy of a Fully Degradable Ventricular Septal Defect (VSD) Closure

Inclusion Criteria: 1. Subjects and/or their legal guardians will be informed of the nature of this study and agree to participate in this clinical trial in accordance with all terms of this study.Signed the informed consent approved by the ethics committee, agreed to accept the postoperative treatment program, and completed the follow-up and related examinations as required by the follow-up; 2. Aged from 1 to 60 years old, weight more than 10 kg, male or non-pregnant women; 3. VSD effective shunt ≥3mm, ≤14mm; 4. Distance between the edge of defect and the right aortic valve is more than 3mm, no aortic valve prolapse or moderate aortic regurgitation. Exclusion Criteria: 1. Irreversible pulmonary vascular disease;Severe pulmonary hypertension with bidirectional shunt; 2. Bleeding disorders or known clotting disorders (including heparin-induced thrombocytopenia),contraindications to antiplatelet therapy, or rejection of transfusions; 3. Sepsis or severe infection within 1 month prior to occlusion; 4. Patients with thrombosis at the occluder placement and venous thrombosis at the catheter insertion site; 5. Cardiac malformation dependent on ventricular septal defect (VSD); 6. Not suitable for treatment with this product.